Wang Wen is the CEO&CMO of IASO BIO, a global clinical-stage biotechnology company with 400+ employees, operating at China and US, dedicated to developing breakthrough cell therapies treating cancer and autoimmune diseases. With $178 Mn USD capital fund raised since 2017, he is leading the company going public and launching the Chinese 1st BCMA-CART therapy to the market treating cancer patients soon. Wen’s work brings hope of cure to many cancer patients including multiple myeloma, a cancer causing over 110,000 annual death; he hopes to change the cancer treatment landscape.